02/09/2026
A triple-blind randomized controlled clinical trial investigated whether organic selenium could provide additional benefits for women with endometriosis. The study included 66 women with confirmed endometriosis and endometriomas, who were randomly assigned to receive either 200 mcg of yeast-based organic selenium or placebo daily for 3 months, alongside routine treatment with 2 mg of dienogest daily. Researchers were particularly interested in selenium because of its antioxidant properties and its role in glutathione peroxidase (GPx), an important antioxidant enzyme, as oxidative stress is thought to contribute to the development and progression of endometriosis.
After three months, women receiving selenium showed a significant reduction in endometrioma size, from an average of 4.82 cm to 3.78 cm, while the average size increased from 4.07 cm to 5.31 cm in the placebo group. Selenium supplementation was also associated with significantly greater improvements in menstrual pain (dysmenorrhea), pain during s*x (dyspareunia), painful urination (dysuria), painful bowel movements (dyschezia), and non-cyclic pain compared with placebo. No serious or health-threatening adverse events were reported.
PMID: 41073678